RT Journal Article
SR Electronic
T1 Genomic risk scores for juvenile idiopathic arthritis and its subtypes
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.02.20.20025924
DO 10.1101/2020.02.20.20025924
A1 Cánovas, Rodrigo
A1 Cobb, Joanna
A1 Brozynska, Marta
A1 Bowes, John
A1 Li, Yun R.
A1 Smith, Samantha L
A1 Hakonarson, Hakon
A1 Thomson, Wendy
A1 Ellis, Justine
A1 Abraham, Gad
A1 Munro, Jane
A1 Inouye, Michael
YR 2020
UL http://medrxiv.org/content/early/2020/03/05/2020.02.20.20025924.abstract
AB Aims Juvenile idiopathic arthritis (JIA) is an autoimmune disease and a common cause of chronic disability in children. Diagnosis of JIA is based purely on clinical symptoms, leading to treatment delays. Despite JIA having substantial heritability, the construction of genomic risk scores (GRSs) to aid or expedite diagnosis has not been assessed. Here, we generate GRSs for JIA and its subtypes and evaluate their performance.Methods We examined three case/control cohorts (UK, US, and Australia) with genome-wide single nucleotide polymorphism (SNP) genotypes. We trained GRSs for JIA and its subtypes using lasso-penalised linear models in cross-validation on the UK cohort, and externally tested in the Australian and US cohorts.Results The JIA GRS alone achieved cross-validated AUC=0.670 in the UK cohort and externally validated AUCs of 0.657 and 0.671 in US-based and Australian cohorts, respectively. In logistic regression of case/control status, the corresponding odds ratios per standard deviation (s.d.) of GRS were 1.831 [1.685-1.991] and 2.008 [1.731-2.345], and were unattenuated by adjustment for sex or the top 10 genetic principal components. Extending our analysis to JIA subtypes revealed that enthesitis-related JIA had both the longest time-to-referral and the subtype GRS with the strongest predictive capacity overall across datasets: AUCs 0.80 in UK; 0.83 Australian; 0.69 US-based. The particularly common oligoarthritis JIA subtype also had a subtype GRS outperformed those for JIA overall, with AUCs of 0.71, 0.75 and 0.77, respectively.Conclusions A genomic risk score for JIA has potential to augment purely clinical JIA diagnosis protocols, prioritising higher-risk individuals for follow-up and treatment. Consistent with JIA heterogeneity, subtype-specific GRSs showed particularly high performance for enthesitis-related and oligoarthritis JIA.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported in part by the Victorian Government’s OIS Program, the Australian National Health and Medical Research Council (NHMRC Project no. 1122744), the Murdoch Children’s Research Institute, and the Royal Children’s Hospital Foundation (grant no. 2017-896). GA was supported by an NHMRC Early Career Fellowship (no. 1090462). MI was supported by the Munz Chair of Cardiovascular Prediction and Prevention. This study acknowledges the use of the following UK JIA cohort collections: The Biologics for Children with Rheumatic Diseases (BCRD) study (funded by Arthritis Research UK Grant 20747). The British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN) (funded by a research grant from the British Society for Rheumatology (BSR). BSR has previously also received restricted income from Pfizer to fund this project). Childhood Arthritis Prospective Study (CAPS) (funded by Versus Arthritis, grant reference number 20542), Childhood Arthritis Response to Medication Study (CHARMS) (funded by Sparks UK, reference 08ICH09, and the Medical Research Council, reference MR/M004600/1), United Kingdom Juvenile Idiopathic Arthritis Genetics Consortium (UKJIAGC). Genotyping of the UK JIA case samples were supported by the Versus Arthritis grants reference numbers 20385 and 21754. This research was funded by the NIHR Manchester Biomedical Research Centre and supported by the Manchester Academic Health Sciences Centre (MAHSC). The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health. We would like to acknowledge the assistance given by IT Services and the use of the Computational Shared Facility at The University of Manchester. Finally, the CHOP data used were funded by an Institute Development Fund to the CAG center from The Children’s Hospital of Philadelphia and by NIH grant, U01-HG006830, from the NHGRIsponsored eMERGE Network.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesFor the individual-level data, note that CHOP is available through the eMERGE Network dbGaP and the WTCCC controls are available through the Wellcome Trust Case Control Consortium webpage https://www.wtccc.org.uk/). For the individual-level genotype data for the UK JIA cases and CLARITY, researchers should contact the cohort PIs (Prof Wendy Thomson [Wendy.Thomson{at}manchester.ac.uk] and Dr Jane Munro [Jane.Munro{at}rch.org.au], respectively). Finally, the JIA GRSs presented will be publicly available to the community via the Polygenic Score Catalog (www.pgscatalog.org) https://www.pgscatalog.org/ https://www.wtccc.org.uk/